Table 3.

Adverse events that arose in at least three patients

Adverse event	All, n (%)	Grade 3/4, n (%)
Sum of all	43 (100.0)	30 (69.8)
Wound dehiscence	11 (25.6)	6 (14.0)
ALP increased	31 (72.1)	4 (9.3)
Blood bilirubin increased	22 (51.2)	4 (9.3)
Hypertriglyceridemia	32 (74.4)	3 (7.0)
Anorexia	20 (46.5)	3 (7.0)
Weight loss	15 (34.9)	3 (7.0)
Pneumothorax	9 (20.9)	3 (7.0)
Platelet count decreased	30 (69.8)	2 (4.7)
Diarrhea	21 (48.8)	2 (4.7)
Hand-foot syndrome	21 (48.8)	2 (4.7)
Pain in extremity	20 (46.5)	2 (4.7)
AST increased	18 (41.9)	2 (4.7)
ALT increased	17 (39.5)	2 (4.7)
Leukopenia	16 (37.2)	2 (4.7)
Rash	14 (32.6)	2 (4.7)
Mucositis oral	11 (25.6)	2 (4.7)
Hypertension	10 (23.3)	2 (4.7)
Abdominal pain	8 (18.6)	2 (4.7)
Toothache	6 (14.0)	2 (4.7)
Non-cardiac chest pain	2 (4.7)	2 (4.7)
Hypothyroidism	35 (81.4)	1 (2.3)
Blood LDH increased	27 (62.8)	1 (2.3)
Proteinuria	11 (25.6)	1 (2.3)
Cough	10 (23.3)	1 (2.3)
Nausea	8 (18.6)	1 (2.3)
Vomiting	6 (14.0)	1 (2.3)
Hemorrhoidal hemorrhage	6 (14.0)	1 (2.3)
Hair color changes	5 (11.6)	0 (0.0)
Fatigue	4 (9.3)	1 (2.3)
Peripheral neuroinflammation	3 (7.0)	1 (2.3)

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase.